Page 457 - Essential Haematology

Index / 443

intestinal lesions, vitamin B 12 iron dextran 45 Kell antigens 402
defi ciency 63 iron overload 51–7 kernicterus, haemolytic disease of
intracranial haemorrhage, neonates African 53 the newborn 422
416 assessment 51, 52 kidneys
intravenous immunoglobulin causes 51 Fanconi’s anaemia 289, 290
(IVIG) 336 hepatic parenchymal cells 51, 52 multiple myeloma 278, 279, 281
intrinsic factor (IF) 60, 61 iron chelation therapy 54–6 sickle cell anaemia 102
antibodies 64 liver 51, 52, 53, 54, 55 see also renal failure
congenital lack/abnormality 64 post-transfusional 53–4, 55, 408 KIT gene mutation, mastocytosis 212
intrinsic Xase 322 thalassaemia major 95 Kleihauer test 419, 420
iron 387 skin pigmentation 54 koilonychia 39, 41
absorption 37–9 treatment 54–6 Kostmann’s syndrome 119
bone marrow stores 42, 43 iron regulatory proteins (IRPs) 36
cycle 35 iron response elements (IREs) 36 L
dietary content 37 lactate dehydrogenase (LDH)
dietary fortifi cation 45 J serum levels

distribution in body 34–7 JAK/STAT 8, 9 in diffuse large B-cell
increased demands 40–1, 42 Janus-associated kinase 2 (JAK2) lymphomas 267
metabolism 34–7 gene mutation 157, 203, in non-Hodgkin lymphoma
nutritional aspects 34, 37–9 204, 205 258
oral 45 essential thrombocythaemia 209 thrombotic thrombocytopenic
parenteral 45 myelodysplastic/ purpura 338
requirements 39, 40 myeloproliferative Langerhans’ cell(s) 121
pregnancy 41 neoplasms 221 Langerhans’ cell histiocytosis 122,
serum levels 42, 43, 425 polycythaemia diagnosis 208 270
status assessment 51, 52 polycythaemia vera 203, 204, large granular lymphocytic
transport 34–7 205 leukaemia (LGL-L) 242,
iron binding capacity 51 primary myelofi brosis 210, 211 243
iron chelation therapy thrombophilia screening 370 lead poisoning 48
iron overload 54–6 venous thrombosis 369 haemolytic anaemia 86
thalassaemia major 98 Janus-associated kinase 2 (JAK2) leg ulceration, sickle cell anaemia
iron defi ciency 34, 39–42, 43, inhibitors 101, 103
44–6 polycythaemia vera 208 leishmaniasis, haematological
causes 40–1 primary myelofi brosis 211 changes 391, 393
clinical features 39–40, 41 Janus-associated kinase (JAK) lenalidomide
congestive heart failure 387 proteins 8, 9, 10 CLL 240
diagnosis 48 jaundice, neonatal 80 multiple myeloma 278, 280
Helicobacter pylori-induced joint deformity/disability, myelodysplasia 219
autoimmune gastritis 64 haemophilia A 346, lepirudin 374, 376
investigations 44–5 347–8, 349 Letterer–Siwe disease 122
iron refractory 46 juvenile myelomonocytic leukaemia leucocyte(s) see white cells
laboratory fi ndings 41–2, 43, 44 192, 221–2 leucocyte adhesion molecules 114
renal failure 387 leucocyte counts 27
treatment 45 K leucocytosis 114–18
iron defi ciency anaemia kala-azar, haematological changes basophil 121
management 44 391, 393 causes 117–18
pregnancy 414 karyotype 156, 157 eosinophilic 120–1
serum ferritin 44 analysis 160 neutrophil 116, 117